Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

Citation record

Study start

2026-01-27

NCT number

NCT07198074

Phase

Phase3

Overall status

Recruiting

Study type

Interventional

Lead sponsor

National Cancer Institute (NCI)

Enrollment

255 participants

Conditions

Advanced Endometrial Carcinoma · Recurrent Endometrial Carcinoma

Interventions

Bevacizumab (Biological) · Biospecimen Collection (Procedure) · Carboplatin (Drug) · Computed Tomography (Procedure) · Magnetic Resonance Imaging (Procedure) · Paclitaxel (Drug)

Last updated at source

23 Oct 2026

Original source

https://clinicaltrials.gov/study/NCT07198074

This page reproduces citation metadata only. Inclusion in the Avion Science research library does not imply endorsement and does not establish the safety, efficacy or intended use of any Avion Science compound. Refer to the original record for complete study information.